Geographically, the global biosimilars market is dominated by europe, followed by asia-pacific, rest of the world (row), and north america however, the asia-pacific region is likely to witness the highest growth rate during the forecast period. Developing iosimilars in emerging markets regulatory and clinical considerations 2 executive summary emerging markets in asia pacific, latin america and eastern. Biosimilars is a massive opportunity regardless of a slow start, the market will eventually be a huge business as per frost & sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and apac’s contribution would be more than 20. With expensive health expenditures and the universal healthcare scheme enjoyed by the public, there are an increasing number of biologics and biosimilar products appearing in the thai market. The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation in the next 4–5 years, two-thirds of the patent.
Biosimilar or follow-on-biologics are similar to the brand biopharmaceutical drugs which are synthetic versions of original products biosimilars have a patent expiration, and their developments are the crucial part of the overall growth of biosimilar market. Biosimilars market - global biosimilars industry size, share, growth, analysis, research and forecast report, 2014 to 2024 global biosimilars market size was valued at 339 billion in 2016 and is expected to grow on account of increasing prevalence of chronic diseases such as cancer and autoimmune disorders. The global biosimilar drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent.
Bcc breaks the biosimilars market into four regions: apac (asia-pacific), the united states, europe, and the rest of the world the apac region accounted for $683 million in 2011 and should reach $11 billion in 2016, a cagr of 103%, according to bcc. The global biosimilars market is expected to reach usd 131 billion by 2024 on account of increase in the prevalence of chronic diseases such as cancer, diabetics, cardiac disorders and autoimmune diseases rising demand for the cost-effective therapies is expected to drive the market in the forecast period biosimilars are about 30% cheaper than their counterpart biologics. Dublin--(business wire)--the apac biosimilar market, forecast 2025 report has been added to researchandmarketscom's offeringthe launch of innovative production platforms will reduce the cost.
The market in the apac region for biosimilars reached $605 million in 2010 and $683 million in 2011 the market is expected to reach $11 billion by 2016, a cagr of 103% the market in the united states for biosimilars reached $507 million in 2010 and $11 billion in 2011. The worldwide market situation with the dispatch of first biosimilar in the market estimates some radical changes this track will view such key concerns which are seen by the worldwide pharma showcase and that are thinking of the consequent dispatch of alternate biosimilars and biologics. Biosimilars market to reach $26,5513 million by 2020 biosimilars market is segmented across north america, europe, asia-pacific and lamea asia pacific and lamea the key companies profiled in this report are novartis (sandoz), synthon pharmaceuticals, inc, teva pharmaceutical industries ltd. Asia pacific biosimilars market is growing at a cagr of 278 % during 2017-2023 market assessment the report for global biosimilars market of market research future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the.
Technavio's report, the global biosimilars market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts the report covers americas, emea and apac regions it also covers the global biosimilars market landscape and its growth prospects in the coming years. Biosimilars is a massive opportunity regardless of a slow start, the market will eventually be a huge business as per frost & sullivan's estimate, biologic drugs worth $70-$80 billion will lose exclusivity in the next 5 years globally and apac's contribution would be more than 20. Biosimilars is a massive opportunity regardless of a slow start, the market will eventually be a huge business as per frost & sullivan's estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and apac's contribution would be more than 20% countries in. Technavio's report, global biosimilars market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts the report covers the market landscape and its growth prospects over the coming years.
Apac biosimilar market, forecast 2025 patent expiries, defined regulatory pathways, and escalating healthcare costs to boost growth biosimilars is a massive opportunity regardless of a slow start, the market will eventually be a huge business. Global biosimilars market 2018-2024 biosimilar is a biologic medicine that is approved based on showing that it is highly similar to an existing approved innovative biological product, known as a reference product. Frost & sullivan’s recent analysis, apac biosimilar market, forecast 2025, provides a detailed assessment of key market dynamics, drivers and restraints, revenue forecasts by region, and market share and competitive analysis.